



Attorney Docket No. 25464X

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Group Art Unit: 1615

GIL-AD et al. Examiner: unknown

Serial No. 10/774,694

Filed: February 10, 2004

For: ANTI-PROLIFERATIVE DRUGS

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. Attached is a copy of the Official Filing Receipt received from the USPTO in the above application for which issuance of a corrected filing receipt is respectfully requested.

2. There is an error with respect to the following data, which is:

 incorrect

X omitted

Error in:

Correct Data:

X Applicant's name

Petition to add inventors concurrently filed;
Liat LOMNITSKI
Eilon ASCULAI

 Applicant's address

 Title


 Filing Date

- Serial Number
 Domestic Priority data as claimed by applicant
 Foreign/PCT Application Re:
 Other

Should any questions or comments arise in connection with the filing of this Request, Applicant respectfully requests a telephone call to the undersigned attorney at the telephone number as shown.

Respectfully submitted,

NATH & ASSOCIATES PLLC




Viviana Amzel
Registration No. 30,930

Customer No. 20529

Date: September 12, 2005

NATH & ASSOCIATES PLLC
1030 15th Street NW, 6th Floor
Washington, D.C. 20005-1503
(202) -775-8383
GMN/dd(Request.cor)



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/774,694	02/10/2004	1615	952	25464X	14	60	6

CONFIRMATION NO. 8587

Gary M. Nath
NATH & ASSOCIATES PLLC
6th Floor
1030 15th Street, N.W.
Washington, DC 20005

UPDATED FILING RECEIPT



OC000000014087894

Date Mailed: 10/14/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Irit Gil-Ad, Herzelia, ISRAEL;
Abraham Weizman, Tel Aviv, ISRAEL;
Add: Liat LOMVITSKI
Eilon ASCULAI

Power of Attorney: None

Domestic Priority data as claimed by applicant

This application is a CIP of 10/432,875 09/16/2003
which is a 371 of PCT/IL01/01105 11/29/2001

Foreign Applications

ISRAEL 139975 11/29/2000

If Required, Foreign Filing License Granted: 05/06/2004

**The number of your priority application, to be used for filing abroad under the Paris Convention is,
US10/774,694**

Projected Publication Date: 01/20/2005

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

Anti-proliferative drugs

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).